Not available
Quote | Benitec Biopharma Limited (NASDAQ:BNTC)
Last: | $9.49 |
---|---|
Change Percent: | 0.69% |
Open: | $9.405 |
Close: | $9.49 |
High: | $9.6 |
Low: | $9.1601 |
Volume: | 24,531 |
Last Trade Date Time: | 05/17/2024 03:00:00 am |
News | Benitec Biopharma Limited (NASDAQ:BNTC)
2024-05-16 18:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-16 10:21:26 ET More on Benitec Benitec GAAP EPS of -$1.64 Benitec Biopharma reports positive data in early study for OPMD treatment Read the full article on Seeking Alpha For further details see: Benitec Biopharma files to sell 32.87M shares of co...
Message Board Posts | Benitec Biopharma Limited (NASDAQ:BNTC)
Subject | By | Source | When |
---|---|---|---|
Got feelins for .56 | Triple nickle | investorshub | 06/26/2023 1:41:41 PM |
No paper trading here | Triple nickle | investorshub | 06/26/2023 1:34:26 PM |
paper trading doesn't count! | TrendTrade2016 | investorshub | 06/26/2023 1:21:20 PM |
Second chance right here | Triple nickle | investorshub | 06/26/2023 1:11:21 PM |
NEWS Benitec Biopharma Receives FDA Clearance of the IND | subslover | investorshub | 06/26/2023 1:05:51 PM |
News, Short Squeeze, Breakout and More Instantly...
Benitec Biopharma Limited Company Name:
BNTC Stock Symbol:
NASDAQ Market:
2024-05-16 18:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
-Positive Interim Clinical Trial Data for the First Oculopharyngeal Muscular Dystrophy (OPMD) Subject Dosed with BB-301 in the Phase 1b/2a Clinical Treatment Study Reported in April- -The Second OPMD Subject was Safely Dosed with BB-301 in February- -Additional Interim Clinical Sa...
HAYWARD, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace...